Antibodies News and Research

RSS

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

Circadian Technologies granted significant European patent

Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.

17 Jun 2009

Pneumococcal vaccine effective in preventing severe pneumonia

A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial - first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.

16 Jun 2009

Discovery of key molecular target in age-related macular degeneration

A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults.

15 Jun 2009

Discovery of DNA mutation that occurs at beginning point of T-cell lymphoma

Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break - an occurrence that marks the first step in the development of human lymphoma.

13 Jun 2009

‘Designer molecules’ being developed to fight disease

Researchers in the Department of Cardiovascular Sciences at the University of Leicester are developing a new way to make protein based drugs with potential applications in stroke, vascular inflammation, blood vessel formation, regenerative medicine and tissue engineering.

11 Jun 2009

New understanding of structure of bacteria responsible for traveler's diarrhea

Researchers at Boston University School of Medicine (BUSM), the Naval Medical Research Center and the National Institutes of Health, have solved the structure of thin hair-like fibers called "pili" or "fimbriae" on the surface of bacteria that cause traveler's diarrhea.

9 Jun 2009

Drug derived from the hydrangea root shows promise for autoimmune disorders

A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine.

4 Jun 2009

New credit card-sized device detects heart disease using less than one drop of blood

Testing people for heart disease might be just a finger prick away thanks to a new credit card-sized device created by a team of researchers from Harvard and Northeastern universities in Boston.

1 Jun 2009

New ultra-sensitive device detects viruses in minutes

Imagine being able to detect in just a few minutes whether someone is infected with a virus. This has now become a reality, thanks to a new ultra-sensitive detector that has been developed by Ostendum, a spin-off company of the University of Twente.

28 May 2009

Experimental therapy uses immune system to boost cure rate in neuroblastoma

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

27 May 2009

HHS directs $1 billion towards commercial-scale production of a candidate vaccine for H1N1

HHS Secretary Kathleen Sebelius has announced that the department will take important steps necessary to prepare for potential commercial-scale production of a candidate vaccine for the novel Influenza A ( H1N1).

24 May 2009

Recommendations by experts to WHO on influenza A (H1N1) vaccines

Current epidemiological information suggests that the influenza A (H1N1) virus transmissibility potential is at least comparable to that of seasonal influenza viruses, with ability to sustain community spread. There is therefore no reason to expect that ongoing spread of the virus will stop.

19 May 2009

Protein neuregulin 1 critical to insulating the body's wiring could also become treatment target

A new protein identified as critical to insulating the wiring that connects the brain and body could one day be a treatment target for divergent diseases, from rare ones that lower the pain threshold to cancer, Medical College of Georgia researchers say.

19 May 2009

Rituximab linked to viral brain infection

The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares.

18 May 2009

Computer simulation captures immune response to flu

Researchers have successfully tested first the first time a computer simulation of major portions of the body's immune reaction to influenza type A, with implications for treatment design and preparation ahead of future pandemics, according to work accepted for publication, and posted online, by the Journal of Virology.

18 May 2009

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

18 May 2009

Piecing together the HIV prevention puzzle

"It's an exciting time in HIV prevention research. We will see results from a number of critically important HIV prevention research trials this year, as well as see the start of new trials around the world that will yield important answers in the years to come," said Mitchell Warren, AVAC executive director, at the release of AVAC's 13th annual report of the field.

18 May 2009

Gene transfer technology may lead to an HIV vaccine

A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.

17 May 2009

Amino acid glutamine show promise in treating stomach ulcers

Nearly 20 years ago, it was discovered that bacteria known as Helicobacter pylori were responsible for stomach ulcers. Since then, antibiotics have become the primary therapy used to combat the H. pylori infection, which affects approximately six percent of the world population and is also a primary cause of stomach cancer. But today the bacteria is growing increasingly resistant to antibiotics.

17 May 2009